Recombinant Lloviu virus as a tool to study viral replication and host responses
Fig 5
Antiviral testing of rLLOVcomp.
(A-D) Testing antiviral compounds against rEBOV-ZsG (gray bars) and rLLOV-ZsG (green bars) in human and bat cells. Huh7 and SuBK12-08 cells were pre-treated with the indicated concentrations of remdesivir (A) or the NPC-1 inhibitor U18666A (B) for 30 minutes, or with universal interferon (U-IFN) for 18 hours (C) prior to infection with rEBOV-ZsG or rLLOV-ZsG at an MOI of 0.1. Fluorescent images were taken at 2 dpi and mean fluorescence relative to infected cells pre-treated with vehicle control are shown. (D) Neutralization assay of rEBOV-ZsG and rLLOV-ZsG at an MOI of 10 using the indicated amounts of EBOV-neutralizing antibody mAb114. Fluorescent images were taken at 2 dpi and relative percentages of infected Huh7 cells are shown. Statistical differences were determined by two-way ANOVA (Prism), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.